Mapi Pharma Granted United States Patent for the Preparation of Fingolimod for Multiple Sclerosis

Mapi Pharma Granted United States Patent for the Preparation of Fingolimod for Multiple Sclerosis

Tuesday, February 18, 2014

Mapi Pharma Granted United States Patent Covering the Process for the Preparation of Fingolimod for Multiple Sclerosis

The patent covers intermediate compounds and processes for the preparation of Fingolimo

Mapi Pharma Ltd. (“Mapi” or the “Company”), a developer of high-barrier to entry and high value-added generic drugs that include complex active pharmaceutical ingredients (“APIs”), formulations and life cycle management (“LCM”) products that target large markets, announced today that it was granted a United States patent covering the process for the preparation of Fingolimod, a drug currently marketed by Novartis under the trade name Gilenya.

Download PDF